-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – FPA-150 in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FPA-150 in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FPA-150 in Metastatic Breast Cancer Drug Details: FPA-150 is under development...
-
Product Insights
Skin And Soft Tissue Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Skin And Soft Tissue Infections - Drugs In Development, 2023’, provides an overview of the Skin And Soft Tissue Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Skin And Soft Tissue Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Congenital Heart Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Congenital Heart Disease - Drugs In Development, 2023’, provides an overview of the Congenital Heart Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Congenital Heart Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PLX-51107 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PLX-51107 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Drug Details: PLX-51107 was under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OPN-2853 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OPN-2853 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OPN-2853 in Solid Tumor Drug Details: PLX-2853 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FORE-8394 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FORE-8394 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Plixorafenib in Solid Tumor Drug Details: FORE-8394 (PLX-8394) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TMB-365 in Human Immunodeficiency Virus (HIV) Infections (AIDS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TMB-365 in Human Immunodeficiency Virus (HIV) Infections (AIDS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.TMB-365 in Human Immunodeficiency Virus (HIV) Infections (AIDS) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nivolumab in Thymic Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in Thymic Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nivolumab in Thymic Carcinoma Drug Details: Nivolumab (Opdivo, Opdyta) is a human...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Avoplacel in Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Avoplacel in Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Avoplacel in Radiation Toxicity (Radiation Sickness, Acute Radiation...